These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35803542)

  • 41. Genetic variability of Polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes.
    Waśko I; Gołębiewska A; Kiedrowska M; Ronkiewicz P; Wróbel-Pawelczyk I; Kuch A; Hong E; Skoczyńska A
    Vaccine; 2020 Feb; 38(8):1943-1952. PubMed ID: 31980191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modeling persistence of hSBA titers over time following a primary series and a booster dose of MenB-FHbp.
    Cai B; Peyrani P; Beeslaar J; Burman C; Balmer P
    Vaccine; 2023 Apr; 41(17):2729-2733. PubMed ID: 37024411
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children.
    Vesikari T; Prymula R; Merrall E; Kohl I; Toneatto D; Dull PM
    Vaccine; 2015 Jul; 33(32):3850-8. PubMed ID: 26141011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.
    Waśko I; Hong E; De Paola R; Stella M; Moschioni M; Taha MK; Skoczyńska A
    Vaccine; 2016 Jan; 34(4):510-515. PubMed ID: 26686998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding immunogenicity assessments for meningococcal serogroup B vaccines.
    Balmer P; Beeslaar J; Findlow J; Srivastava A
    Postgrad Med; 2020 Mar; 132(2):184-191. PubMed ID: 32124678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.
    Snape MD; Voysey M; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Kieninger D; Prymula R; Dull PM; Kohl I; Barone M; Wang H; Toneatto D; Pollard AJ;
    Pediatr Infect Dis J; 2016 Apr; 35(4):e113-23. PubMed ID: 26756390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.
    Marjuki H; Chang HY; Topaz N; Whaley MJ; Vuong J; Chen A; Jenkins LT; Hu F; Schmink S; Retchless AC; Thomas JD; Acosta AM; McNamara LA; Soeters HM; Mbaeyi S; Wang X
    mBio; 2021 May; 12(3):. PubMed ID: 34006659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans.
    Toneatto D; Ismaili S; Ypma E; Vienken K; Oster P; Dull P
    Hum Vaccin; 2011 Jun; 7(6):646-53. PubMed ID: 21904120
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.
    Tzanakaki G; Hong E; Kesanopoulos K; Xirogianni A; Bambini S; Orlandi L; Comanducci M; Muzzi A; Taha MK
    BMC Microbiol; 2014 Apr; 14():111. PubMed ID: 24779381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine.
    Lucidarme J; Comanducci M; Findlow J; Gray SJ; Kaczmarski EB; Guiver M; Vallely PJ; Oster P; Pizza M; Bambini S; Muzzi A; Borrow R
    Clin Vaccine Immunol; 2010 Jun; 17(6):919-29. PubMed ID: 20375242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
    Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
    Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine.
    Santolaya ME; O'Ryan M; Valenzuela MT; Prado V; Vergara RF; Muñoz A; Toneatto D; Graña G; Wang H; Dull PM
    Hum Vaccin Immunother; 2013 Nov; 9(11):2304-10. PubMed ID: 23811804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
    Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial.
    Martinón-Torres F; Carmona Martinez A; Simkó R; Infante Marquez P; Arimany JL; Gimenez-Sanchez F; Couceiro Gianzo JA; Kovács É; Rojo P; Wang H; Bhusal C; Toneatto D
    J Infect; 2018 Mar; 76(3):258-269. PubMed ID: 29253560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.
    Costa I; Pajon R; Granoff DM
    mBio; 2014 Aug; 5(5):e01625-14. PubMed ID: 25161192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015-2018: Evolution of the vaccine antigen factor H binding protein (FHbp).
    Abad R; García-Amil C; Navarro C; Martín E; Martín-Díaz A; Vázquez JA
    J Infect; 2021 Apr; 82(4):37-44. PubMed ID: 33610688
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome.
    Mülling N; Rohn H; Vogel U; Claus H; Wilde B; Eisenberger U; Kribben A; Witzke O; Gäckler A
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32159209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II).
    Esposito S; Prymula R; Zuccotti GV; Xie F; Barone M; Dull PM; Toneatto D
    Hum Vaccin Immunother; 2014; 10(7):2005-14. PubMed ID: 25424810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.